These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19779026)

  • 21. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What are the risks of long-term NSAIDs and COX-2 inhibitors?
    DeBisschop M
    J Fam Pract; 2003 Mar; 52(3):199-200. PubMed ID: 12620173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-dependent immunomodulatory effects of acetylsalicylic acid and indomethacin in human whole blood: potential role of cyclooxygenase-2 inhibition.
    Härtel C; von Puttkamer J; Gallner F; Strunk T; Schultz C
    Scand J Immunol; 2004 Oct; 60(4):412-20. PubMed ID: 15379866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of rheumatoid arthritis and osteoarthritis with COX-2-selective inhibitors: a managed care perspective.
    Hochberg MC
    Am J Manag Care; 2002 Nov; 8(17 Suppl):S502-17. PubMed ID: 12458820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction.
    Andersohn F; Suissa S; Garbe E
    Circulation; 2006 Apr; 113(16):1950-7. PubMed ID: 16618816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Biology of Prostanoids and Drug Discovery.
    Zhu L; Zhang Y; Guo Z; Wang M
    Arterioscler Thromb Vasc Biol; 2020 Jun; 40(6):1454-1463. PubMed ID: 32295420
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Side effects of COX-2 selective inhibitors. Critic related with its administration in patients with rheumatoid arthritis and osteoarthritis].
    Carrillo Gutiérrez OY; Pérez Sánchez AG; Medina Serriteño N; Rodríguez Orozco AR
    Rev Alerg Mex; 2007; 54(4):116-22. PubMed ID: 18297851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccines against atherosclerosis.
    Nilsson J; Wigren M; Shah PK
    Expert Rev Vaccines; 2013 Mar; 12(3):311-21. PubMed ID: 23496670
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Thoughts on the "COX-2 story"].
    Kurz H
    Wien Med Wochenschr; 2005 May; 155(9-10):205-6. PubMed ID: 15999626
    [No Abstract]   [Full Text] [Related]  

  • 32. The anti-inflammatory effects of ketamine: state of the art.
    Loix S; De Kock M; Henin P
    Acta Anaesthesiol Belg; 2011; 62(1):47-58. PubMed ID: 21612145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging role of Th1 cells in atherosclerosis and its implications for therapy.
    Chen J; Xiang X; Nie L; Guo X; Zhang F; Wen C; Xia Y; Mao L
    Front Immunol; 2022; 13():1079668. PubMed ID: 36685487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prostanoids and NSAIDs in cardiovascular biology and disease.
    Weksler BB
    Curr Atheroscler Rep; 2015 Jul; 17(7):41. PubMed ID: 26017392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COX-2 expression in atherosclerosis: the good, the bad or the ugly?
    Cuccurullo C; Fazia ML; Mezzetti A; Cipollone F
    Curr Med Chem; 2007; 14(15):1595-605. PubMed ID: 17584067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calculated effect of fluid retention upon velocity of blood flow and turbulence: implications for atherosclerosis.
    Blankfield RP
    Clin Hemorheol Microcirc; 2011; 47(2):79-86. PubMed ID: 21339628
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel determinants of plaque instability.
    Cipollone F; Fazia M; Mezzetti A
    J Thromb Haemost; 2005 Sep; 3(9):1962-75. PubMed ID: 16102103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response to the letter to the editor entitled "diclofenac: increase of myocardial infarctions at low doses?" (PDS 13-0441) authored by K Brune.
    Varas-Lorenzo C; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2014 Mar; 23(3):329-30. PubMed ID: 24596324
    [No Abstract]   [Full Text] [Related]  

  • 39. Response to "No Obvious Extra Cardiovascular Risk Associated With Low-Dose NSAIDs," "Do NSAIDs Actually Protect Against Myocardial Infarction and Death?," and "Are Myocardial Infarctions and Death in Healthy Individuals Associated With the Use of Cyclooxygenase Inhibitors?".
    Fosbøl EL; Gislason GH; Køber L; Torp-Pedersen C
    Clin Pharmacol Ther; 2009 Dec; 86(6):602-604. PubMed ID: 28547832
    [No Abstract]   [Full Text] [Related]  

  • 40. Eicosanoid production by parasites: from pathogenesis to immunomodulation?
    Belley A; Chadee K
    Parasitol Today; 1995 Sep; 11(9):327-34. PubMed ID: 15275314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.